Day One Biopharmaceuticals Inc (NASDAQ: DAWN) has experienced a decline in its stock price by -1.15 compared to its previous closing price of 13.01. However, the company has seen a gain of 2.80% in its stock price over the last five trading days. seekingalpha.com reported 2025-01-07 that Day One Biopharmaceuticals focuses on pediatric cancer treatments, with a promising pipeline including tovorafenib and other targeted therapies. The stock has experienced a bearish trend but has significant upside potential, with Wall Street targeting a 190% increase. Strong financial position with $558.4M in cash and a cash runway of over 3 years significantly reducing the dilution risk.
Is It Worth Investing in Day One Biopharmaceuticals Inc (NASDAQ: DAWN) Right Now?
The stock has a 36-month beta value of -1.45. Opinions on the stock are mixed, with 4 analysts rating it as a “buy,” 5 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for DAWN is 72.64M, and at present, short sellers hold a 22.85% of that float. On January 31, 2025, the average trading volume of DAWN was 1.15M shares.
DAWN’s Market Performance
DAWN’s stock has seen a 2.80% increase for the week, with a -0.08% drop in the past month and a -11.13% fall in the past quarter. The volatility ratio for the week is 4.88%, and the volatility levels for the past 30 days are at 4.34% for Day One Biopharmaceuticals Inc. The simple moving average for the past 20 days is 4.01% for DAWN’s stock, with a -8.57% simple moving average for the past 200 days.
Analysts’ Opinion of DAWN
Many brokerage firms have already submitted their reports for DAWN stocks, with Needham repeating the rating for DAWN by listing it as a “Buy.” The predicted price for DAWN in the upcoming period, according to Needham is $33 based on the research report published on October 09, 2024 of the previous year 2024.
BofA Securities, on the other hand, stated in their research note that they expect to see DAWN reach a price target of $24, previously predicting the price at $11. The rating they have provided for DAWN stocks is “Buy” according to the report published on August 01st, 2024.
Needham gave a rating of “Buy” to DAWN, setting the target price at $33 in the report published on April 24th of the previous year.
DAWN Trading at -0.00% from the 50-Day Moving Average
After a stumble in the market that brought DAWN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -28.83% of loss for the given period.
Volatility was left at 4.34%, however, over the last 30 days, the volatility rate increased by 4.88%, as shares surge +2.23% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -10.20% lower at present.
During the last 5 trading sessions, DAWN rose by +2.80%, which changed the moving average for the period of 200-days by -6.61% in comparison to the 20-day moving average, which settled at $12.36. In addition, Day One Biopharmaceuticals Inc saw 1.50% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DAWN starting from Blackman Samuel C., who sale 30,000 shares at the price of $13.31 back on Dec 10 ’24. After this action, Blackman Samuel C. now owns 1,034,015 shares of Day One Biopharmaceuticals Inc, valued at $399,339 using the latest closing price.
Bender Jeremy, the CHIEF EXECUTIVE OFFICER of Day One Biopharmaceuticals Inc, sale 10,554 shares at $13.21 during a trade that took place back on Nov 18 ’24, which means that Bender Jeremy is holding 108,377 shares at $139,420 based on the most recent closing price.
Stock Fundamentals for DAWN
Current profitability levels for the company are sitting at:
- -2.06 for the present operating margin
- 0.97 for the gross margin
The net margin for Day One Biopharmaceuticals Inc stands at -0.82. The total capital return value is set at -0.38. Equity return is now at value -17.84, with -16.61 for asset returns.
Based on Day One Biopharmaceuticals Inc (DAWN), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -34.22.
Currently, EBITDA for the company is -206.06 million with net debt to EBITDA at 1.99. When we switch over and look at the enterprise to sales, we see a ratio of 8.55. The receivables turnover for the company is 11.79for trailing twelve months and the total asset turnover is 0.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 14.62.
Conclusion
To sum up, Day One Biopharmaceuticals Inc (DAWN) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
